Lv51
922 积分 2021-04-09 加入
有志者，事竟成！
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
16小时前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
16小时前
已完结
When TNM Staging Is Not Sufficient
12天前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
14天前
已完结
p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
14天前
已完结
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial
1个月前
已完结
Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
1个月前
已完结
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
1个月前
已完结
Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
2个月前
已完结
The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)
2个月前
已完结
皖公网安备34019202002308
